Kala Bio signs LOI to buy nationwide telehealth platform for about $15 million
KALA•Kala Bio signed a non-binding letter of intent to acquire a privately held company supporting a 50-state telehealth platform for about $15 million in cash and stock. The target reported $12.7 million in trailing-12-month revenue through August 2026 and was described by management as cash-flow positive.
1. Proposed acquisition
Kala Bio signed a non-binding letter of intent to acquire a privately held management services organization supporting a nationwide telehealth platform, in a transaction valued at about $15 million. Payment would be in cash and Kala stock, with the cash portion expected to come from existing balance-sheet resources.
2. Platform and timeline
The target reported $12.7 million in trailing-12-month revenue through August 2026, and management described the business as cash-flow positive. The platform has served more than 90,000 clients since 2023 and recorded more than $48 million in sales since inception. Due diligence is set for 45 days and is expected to end in November 2026; closing is targeted for late 2026 or early 2027.
